declared on May 7, 2010 that its bevacizumab
injection (brand name ""Avastin"") was approved by the FDA for curing metastatic colorectal cancer.
For patients who received bevacizumab
with chemotherapy followed by bevacizumab
for up to an additional 10 months, the median time until their cancer progressed was 14.
The evidence we have suggests that patients receiving bevacizumab
and chemotherapy for this indication may survive on average for six weeks longer than patients receiving chemotherapy and placebo.
Ian Beaumont, campaigns director at Bowel Cancer UK, said: "We are naturally disappointed that Nice has turned down bevacizumab
(Avastin) for use on the NHS when there is so much evidence of the treatment's efficacy and it is so widely available to patients across the rest of Europe.
As such, it provides a more accurate risk estimate than the rather alarming 16% incidence reported by Greek investigators in 116 patients on a bisphosphonate plus bevacizumab
or another antiangiogenesis agent, sunitinib (Oncology 2009;76:209-11), Dr.
To the investigators' surprise, a host of potential causes--among them, the number of previous bevacizumab
(Avastin) regimens, carcinomatosis, bowel involvement on CT scan, and history of small bowel obstruction--produced no significant associations with bowel complications.
Moreover, it has also been demonstrated in randomised Phase II studies , and in a combined analysis of these Phase II studies , that bevacizumab
increases the activity of 5-FU/LV in first-line treatment of metastatic CRC.
These results were driven by targeting anti-angiogenic therapy to patients shown to respond and discontinuing the addition of bevacizumab
to standard chemotherapy regimens in biomarker-identified non-responders.
A comprehensive review of clinical studies that have identified biomarkers that are either therapy-indicating in respect of bevacizumab
(Avastin) or indicative of patient prognosis
Ipilimumab has extended the lives of metastatic melanoma patients in previous clinical trials, and bevacizumab
is often used to treat tumors of the colon, lung, and kidney.
Nice said it had looked at evidence from the manufacturer, Roche, which "did not show bevacizumab
to significantly improve or extend the lives of breast cancer patients".
For advanced disease, patients are usually treated with a sequence of regimens including FOLFIRI or FOLFOX, often in combination with an antibody such as bevacizumab
TAMPA -- Bevacizumab
appeared to be active and well tolerated in a small phase II Gynecologic Oncology Group study of women with recurrent squamous cell cervical cancer, Dr.
have announced "accelerated approval" of bevacizumab
in combination with paclitaxel for treating patients who have not received chemotherapy for metastatic HER2-negative breast cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, FOLFIRI* plus bevacizumab
(Genentech/Roche/Chugai's Avastin) has earned Decision Resources' proprietary clinical gold-standard status for the second-line treatment of metastatic colorectal cancer (mCRC).